Vertex Pharmaceuticals Inc - Asset Resilience Ratio
Vertex Pharmaceuticals Inc (VRTX) has an Asset Resilience Ratio of 6.23% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See VRTX current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2000–2025)
This chart shows how Vertex Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see total assets of Vertex Pharmaceuticals Inc.
Liquid Assets Composition Over Time
This chart breaks down Vertex Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore VRTX long-term investments to assets to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.71 Billion | 6.23% |
| Total Liquid Assets | $1.71 Billion | 6.23% |
Asset Resilience Insights
- Limited Liquidity: Vertex Pharmaceuticals Inc maintains only 6.23% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Vertex Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Vertex Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for Vertex Pharmaceuticals Inc (2000–2025)
The table below shows the annual Asset Resilience Ratio data for Vertex Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 5.83% | $1.52 Billion | $26.14 Billion | -1.04pp |
| 2024-12-31 | 6.86% | $1.55 Billion | $22.53 Billion | +3.13pp |
| 2023-12-31 | 3.74% | $849.20 Million | $22.73 Billion | +2.22pp |
| 2022-12-31 | 1.51% | $274.50 Million | $18.15 Billion | -3.92pp |
| 2021-12-31 | 5.43% | $729.90 Million | $13.43 Billion | -0.27pp |
| 2020-12-31 | 5.71% | $670.70 Million | $11.75 Billion | -2.70pp |
| 2019-12-31 | 8.40% | $698.97 Million | $8.32 Billion | +0.11pp |
| 2018-12-31 | 8.30% | $518.11 Million | $6.25 Billion | -3.64pp |
| 2017-12-31 | 11.94% | $423.25 Million | $3.55 Billion | +3.28pp |
| 2016-12-31 | 8.66% | $250.61 Million | $2.89 Billion | -4.46pp |
| 2015-12-31 | 13.12% | $327.69 Million | $2.50 Billion | -19.49pp |
| 2014-12-31 | 32.61% | $761.85 Million | $2.34 Billion | -6.02pp |
| 2013-12-31 | 38.63% | $895.78 Million | $2.32 Billion | +8.48pp |
| 2012-12-31 | 30.15% | $831.81 Million | $2.76 Billion | +7.75pp |
| 2011-12-31 | 22.39% | $493.60 Million | $2.20 Billion | -23.29pp |
| 2010-12-31 | 45.68% | $788.21 Million | $1.73 Billion | +2.82pp |
| 2009-12-31 | 42.87% | $838.25 Million | $1.96 Billion | -2.31pp |
| 2008-12-31 | 45.18% | $442.99 Million | $980.48 Million | +27.69pp |
| 2007-12-31 | 17.49% | $105.21 Million | $601.48 Million | -35.84pp |
| 2006-12-31 | 53.33% | $491.45 Million | $921.58 Million | +1.76pp |
| 2005-12-31 | 51.57% | $283.11 Million | $549.00 Million | -10.27pp |
| 2004-12-31 | 61.84% | $337.31 Million | $545.45 Million | -5.11pp |
| 2003-12-31 | 66.95% | $485.00 Million | $724.41 Million | +2.36pp |
| 2002-12-31 | 64.59% | $526.89 Million | $815.72 Million | +4.71pp |
| 2001-12-31 | 59.88% | $554.00 Million | $925.13 Million | +51.28pp |
| 2000-12-31 | 8.61% | $66.51 Million | $772.88 Million | -- |
About Vertex Pharmaceuticals Inc
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with C… Read more